|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
91,730,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Athenex is a biopharmaceutical company focused on the discovery, development and commercialization of drugs for cancer treatment. Co.'s platforms are: Oncology Innovation Platform, which is focused on the research and development of its proprietary drugs; Commercial Platform, which is focused on the sales and marketing of its drugs and the market development of its proprietary drugs; and Global Supply Chain Platform, which provides supply of active pharmaceutical ingredients for its clinical and commercial efforts. Co.'s clinical pipeline in the Oncology Innovation Platform is derived from Cell Therapy, Orascovery, based on a P-glycoprotein pump inhibitor, and Src Kinase inhibition.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$13,319 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Cook Timothy Devere |
See Remarks |
• – – |
2022-09-09 |
4 |
A |
$0.46 |
$500 |
D/D |
1,079 |
12,215 |
|
- |
|
| Kwan Rudolf |
EVP, Chief Medical Officer |
• – – |
2022-09-09 |
4 |
A |
$0.46 |
$4,900 |
D/D |
10,572 |
321,391 |
|
- |
|
| Lau Johnson Yiu Nam |
CEO and Chairman of the Board |
• • – |
2022-09-09 |
4 |
A |
$0.46 |
$11,400 |
D/D |
24,596 |
3,601,839 |
|
- |
|
| Lau Johnson Yiu Nam |
CEO and Chairman of the Board |
• • – |
2022-08-26 |
4 |
A |
$0.47 |
$11,400 |
D/D |
24,071 |
3,577,243 |
|
- |
|
| Kwan Rudolf |
EVP, Chief Medical Officer |
• – – |
2022-08-26 |
4 |
A |
$0.47 |
$4,900 |
D/D |
10,346 |
310,819 |
|
- |
|
| Cook Timothy Devere |
See Remarks |
• – – |
2022-08-26 |
4 |
A |
$0.47 |
$500 |
D/D |
1,056 |
11,136 |
|
- |
|
| Wu Jinn |
Director |
– • – |
2022-08-22 |
4 |
B |
$0.42 |
$4,221 |
D/D |
10,000 |
484,783 |
2.31 |
- |
|
| Lau Johnson Yiu Nam |
CEO and Chairman of the Board |
• • – |
2022-08-19 |
4 |
B |
$0.45 |
$9,098 |
D/D |
20,000 |
3,553,172 |
2.81 |
- |
|
| Lau Johnson Yiu Nam |
CEO and Chairman of the Board |
• • – |
2022-08-12 |
4 |
A |
$0.52 |
$11,400 |
D/D |
21,923 |
3,533,172 |
|
- |
|
| Kwan Rudolf |
EVP, Chief Medical Officer |
• – – |
2022-08-12 |
4 |
A |
$0.52 |
$4,900 |
D/D |
9,423 |
300,473 |
|
- |
|
| Cook Timothy Devere |
See Remarks |
• – – |
2022-08-12 |
4 |
A |
$0.52 |
$500 |
D/D |
961 |
10,080 |
|
- |
|
| Fok Manson |
Director |
– • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
2,027,102 |
|
- |
|
| Davis Stephanie A |
Director |
– • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,750 |
42,204 |
|
- |
|
| Kanfer Jordan |
Director |
– • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
17,086 |
|
- |
|
| Tsang Benson Kwan Hung |
Director |
– • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
52,572 |
|
- |
|
| Wu Jinn |
Director |
– • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
474,783 |
|
- |
|
| Vierling John |
Director |
– • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
35,325 |
|
- |
|
| Spiegel Robert J. |
Director |
– • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,750 |
17,247 |
|
- |
|
| Lau Johnson Yiu Nam |
CEO and Chairman of the Board |
• • – |
2022-08-03 |
4 |
D |
$0.58 |
$5,302 |
D/D |
(9,132) |
3,511,249 |
|
- |
|
| Lau Johnson Yiu Nam |
CEO and Chairman of the Board |
• • – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
3,520,381 |
|
- |
|
| Yordon Jeffrey |
See Remarks |
• – – |
2022-08-03 |
4 |
D |
$0.58 |
$2,127 |
D/D |
(3,663) |
245,943 |
|
- |
|
| Yordon Jeffrey |
See Remarks |
• – – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,500 |
249,606 |
|
- |
|
| Kwan Rudolf |
EVP, Chief Medical Officer |
• – – |
2022-08-03 |
4 |
D |
$0.58 |
$2,475 |
D/D |
(4,262) |
291,050 |
|
- |
|
| Kwan Rudolf |
EVP, Chief Medical Officer |
• – – |
2022-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,500 |
295,312 |
|
- |
|
| Cook Timothy Devere |
See Remarks |
• – – |
2022-07-29 |
4 |
A |
$0.51 |
$500 |
D/D |
986 |
9,119 |
|
- |
|
371 Records found
|
|
Page 4 of 15 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
